source
- Experts tout amylin as promising, potentially gentler obesity target as new combo therapies near FDA reviewWhile GLP-1 medicines dominate the weight‑loss market, some observers argue that amylin would have been the logical primary target for obesity treatment a decade ago. Novo Nordisk’s amylin/GLP‑1 c…
- Arbitrators profit heavily from No Surprises Act disputes, raising concerns over health-care billing practicesThe STAT Health Care Inc. newsletter reports that the arbitration mechanism created by the No Surprises Act, intended to resolve out-of-network billing conflicts, has become a lucrative business fo…